131 related articles for article (PubMed ID: 37260251)
1. Safety and tolerability of isoniazid preventive therapy for tuberculosis for persons with HIV with and without alcohol use.
Hahn JA; Ngabirano C; Fatch R; Emenyonu NI; Cheng DM; Adong J; Tumwegamire A; Terrault NA; Linas BP; Jacobson KR; Muyindike WR
AIDS; 2023 Aug; 37(10):1535-1543. PubMed ID: 37260251
[TBL] [Abstract][Full Text] [Related]
2. The Drinkers' Intervention to Prevent Tuberculosis (DIPT) trial among heavy drinkers living with HIV in Uganda: study protocol of a 2×2 factorial trial.
Lodi S; Emenyonu NI; Marson K; Kwarisiima D; Fatch R; McDonell MG; Cheng DM; Thirumurthy H; Gandhi M; Camlin CS; Muyindike WR; Hahn JA; Chamie G
Trials; 2021 May; 22(1):355. PubMed ID: 34016158
[TBL] [Abstract][Full Text] [Related]
3. Isoniazid-associated hepatitis and antiretroviral drugs during tuberculosis prophylaxis in hiv-infected adults in Botswana.
Tedla Z; Nyirenda S; Peeler C; Agizew T; Sibanda T; Motsamai O; Vernon A; Wells CD; Samandari T
Am J Respir Crit Care Med; 2010 Jul; 182(2):278-85. PubMed ID: 20378730
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.
Ngongondo M; Miyahara S; Hughes MD; Sun X; Bisson GP; Gupta A; Kumwenda J; Lavenberg JA; Torres TS; Nyirenda M; Kidonge KK; Hosseinipour MC;
J Acquir Immune Defic Syndr; 2018 May; 78(1):54-61. PubMed ID: 29406428
[TBL] [Abstract][Full Text] [Related]
5. Isoniazid Preventive Therapy for People With HIV Who Are Heavy Alcohol Drinkers in High TB-/HIV-Burden Countries: A Risk-Benefit Analysis.
Freiman JM; Jacobson KR; Muyindike WR; Horsburgh CR; Ellner JJ; Hahn JA; Linas BP
J Acquir Immune Defic Syndr; 2018 Apr; 77(4):405-412. PubMed ID: 29239900
[TBL] [Abstract][Full Text] [Related]
6. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
[TBL] [Abstract][Full Text] [Related]
7. Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda.
Muyindike WR; Fatch R; Cheng DM; Emenyonu NI; Forman L; Ngabirano C; Adong J; Linas B; Jacobson KR; Hahn JA
J Acquir Immune Defic Syndr; 2022 Dec; 91(5):460-468. PubMed ID: 36044285
[TBL] [Abstract][Full Text] [Related]
8. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda.
Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D
AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788
[TBL] [Abstract][Full Text] [Related]
9. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic.
Fountain FF; Tolley E; Chrisman CR; Self TH
Chest; 2005 Jul; 128(1):116-23. PubMed ID: 16002924
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of elevated liver transaminases and their relationship with alcohol use in people living with HIV on anti-retroviral therapy in Uganda.
Freiman JM; Fatch R; Cheng D; Emenyonu N; Ngabirano C; Geadas C; Adong J; Muyindike WR; Linas BP; Jacobson KR; Hahn JA
PLoS One; 2021; 16(6):e0250368. PubMed ID: 34061870
[TBL] [Abstract][Full Text] [Related]
11. Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study.
Gray DM; Workman LJ; Lombard CJ; Jennings T; Innes S; Grobbelaar CJ; Cotton MF; Zar HJ
Int J Tuberc Lung Dis; 2014 Mar; 18(3):322-7. PubMed ID: 24670570
[TBL] [Abstract][Full Text] [Related]
12. Tuberculosis vaccination versus isoniazid preventive therapy: a decision analysis to determine the preferred strategy of tuberculosis prevention in HIV-infected adults in the developing world.
Sterling TR; Brehm WT; Moore RD; Chaisson RE
Int J Tuberc Lung Dis; 1999 Mar; 3(3):248-54. PubMed ID: 10094327
[TBL] [Abstract][Full Text] [Related]
13. Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Gao XF; Wang L; Liu GJ; Wen J; Sun X; Xie Y; Li YP
Int J Tuberc Lung Dis; 2006 Oct; 10(10):1080-90. PubMed ID: 17044199
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid-associated hepatitis in adults infected with HIV receiving 36 months of isoniazid prophylaxis in Botswana.
Tedla Z; Nguyen ML; Sibanda T; Nyirenda S; Agizew TB; Girde S; Rose CE; Samandari T
Chest; 2015 May; 147(5):1376-1384. PubMed ID: 25340318
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety, and tolerability of isoniazid preventive therapy for tuberculosis in people living with HIV.
Jagi JL; Thomas C; Gudi SK; Undela K
AIDS; 2023 Mar; 37(3):455-465. PubMed ID: 36412204
[TBL] [Abstract][Full Text] [Related]
16. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study.
Tweed CD; Wills GH; Crook AM; Dawson R; Diacon AH; Louw CE; McHugh TD; Mendel C; Meredith S; Mohapi L; Murphy ME; Murray S; Murthy S; Nunn AJ; Phillips PPJ; Singh K; Spigelman M; Gillespie SH
BMC Med; 2018 Mar; 16(1):46. PubMed ID: 29592805
[TBL] [Abstract][Full Text] [Related]
17. Adherence to Isoniazid Preventive Therapy among children living with tuberculosis patients in Delhi, India: An exploratory prospective study.
Sharma N; Basu S; Khanna A; Sharma P; Chopra KK; Chandra S
Indian J Tuberc; 2022 Jan; 69(1):100-103. PubMed ID: 35074140
[TBL] [Abstract][Full Text] [Related]
18. Transaminitis prevalence among HIV-infected adults eligible for tuberculosis preventive therapy.
Chaisson LH; Semitala FC; Mwebe S; Katende J; Asege L; Nakaye M; Andama AO; Atuhumuza E; Kamya M; Cattamanchi A; Yoon C
AIDS; 2022 Sep; 36(11):1591-1595. PubMed ID: 35730395
[TBL] [Abstract][Full Text] [Related]
19. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons?
Gordin FM; Cohn DL; Matts JP; Chaisson RE; O'Brien RJ; ; ;
Clin Infect Dis; 2004 Aug; 39(4):561-5. PubMed ID: 15356822
[TBL] [Abstract][Full Text] [Related]
20. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
